Focus Areas
We are committed to reimagining cancer care and focused on advancing solutions that support patient journeys and provide meaningful and differentiated results. With that commitment in mind, we are working to unlock the full potential of our pipeline by continuing to investigate the science of our first-in-class therapeutics, revumenib and axatilimab, while pursuing select licensing and partnership opportunities with other industry leaders that closely align to our mission.
Leukemia is a type of blood cancer that takes place in the bone marrow where normal blood cells are made. It starts with a single stem cell that becomes a leukemia (blast) cell. With acute leukemia, the abnormal leukemia cells multiply very quickly and take over the space in the bone marrow, which blocks the cells from turning into normal healthy blood cells. Acute lymphoid leukemia and acute myeloid leukemia are two different types of acute leukemia that stop cells from developing into healthy blood cells and lower your healthy blood cell counts.
Chronic graft-versus-host disease (GVHD) continues to cause significant morbidity and mortality among patients following transplant. We estimate that approximately 14,000 U.S. patients suffer from chronic GVHD, 50% of whom require therapeutic intervention beyond second line due to disease progression, inadequate response, or disease manifestations that aren’t fully addressed. This disease typically manifests across multiple organ systems, with skin and mucosa being commonly involved, and is characterized by the development of fibrotic tissue.
At Syndax, we are advancing the next generation of targeted treatments to realize a future in which people with cancer live longer and better than ever before.
We have a proven ability to advance innovative and differentiated cancer programs and a strong record of adhering to scientific excellence, following promising clinical data and real-world utilization.